PRKDC在头颈部肿瘤中的研究进展
Research Progress of PRKDC in Head and Neck Tumors
DOI: 10.12677/acm.2025.15113243, PDF,   
作者: 许海龙*, 黄萍萍, 陈小素：右江民族医学院研究生学院，广西 百色；韦富贵#：广西科技大学第二附属医院(第二临床医学院)耳鼻咽喉头颈外科，广西 柳州
关键词: PRKDC；头颈部肿瘤；DNA修复；肿瘤微环境；临床应用；PRKDC； Head and Neck Tumors； DNA Repair； Tumor Microenvironment； Clinical Application
摘要: PRKDC (蛋白激酶DNA依赖性复合体)在头颈部肿瘤的发生与发展中扮演着重要角色，近年来相关研究不断增多，揭示了其在DNA修复、细胞增殖及肿瘤微环境中的多重功能。PRKDC作为DNA修复过程中的关键因子，与肿瘤细胞的增殖和耐药性密切相关，影响着肿瘤的生物学特性和临床预后。研究表明，PRKDC不仅参与DNA损伤反应，还与多种肿瘤相关信号通路相互作用，推动肿瘤的进展。此外，PRKDC的表达水平与肿瘤的侵袭性和患者的生存率存在关联，为其在临床应用提供了潜在依据。头颈部肿瘤是全球范围内常见的恶性肿瘤之一，其治疗仍面临诸多挑战，因此，探索肿瘤发生机制和寻找新的靶点显得尤为重要。本文综述了PRKDC在头颈部肿瘤中的最新研究进展，探讨其分子机制、临床应用现状及未来研究方向，旨在为头颈部肿瘤的治疗提供新的思路和视角。
Abstract: PRKDC (Protein Kinase DNA-Dependent Complex) plays an important role in the occurrence and development of head and neck tumors. In recent years, related research has been increasing, revealing its multiple functions in DNA repair, cell proliferation, and the tumor microenvironment. As a key factor in DNA repair, PRKDC is closely related to the proliferation and drug resistance of tumor cells, affecting the biological characteristics and clinical prognosis of tumors. Studies have shown that PRKDC is not only involved in the DNA damage response but also interacts with various tumor-related signaling pathways, promoting tumor progression. In addition, the expression level of PRKDC is associated with the invasiveness of tumors and patient survival rates, providing a potential basis for its clinical application. Head and neck tumors are one of the common malignant tumors worldwide, and their treatment still faces many challenges. Therefore, exploring the mechanisms of tumor occurrence and seeking new targets are particularly important. This article reviews the latest research progress of PRKDC in head and neck tumors, discusses its molecular mechanisms, current status of clinical application, and future research directions, aiming to provide new ideas and perspectives for the treatment of head and neck tumors.
文章引用：许海龙, 韦富贵, 黄萍萍, 陈小素. PRKDC在头颈部肿瘤中的研究进展[J]. 临床医学进展, 2025, 15(11): 1463-1468. https://doi.org/10.12677/acm.2025.15113243

参考文献

[1] Avril, D., Foy, J., Bouaoud, J., Grégoire, V. and Saintigny, P. (2022) Biomarkers of Radioresistance in Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Biology, 99, 583-593. [Google Scholar] [CrossRef] [PubMed]
[2] García-Chávez, J.N., Contreras-Paredes, A., González-Espinosa, C., Martínez-Ramírez, I., Langley, E., Lizano, M., et al. (2025) Association of Gene Expression Profiles in HPV-Positive Head and Neck Squamous Cell Carcinoma with Patient Outcome: In Search of Prognostic Biomarkers. International Journal of Molecular Sciences, 26, Article 5894. [Google Scholar] [CrossRef] [PubMed]
[3] Tran, N.H., Sais, D. and Tran, N. (2024) Advances in Human Papillomavirus Detection and Molecular Understanding in Head and Neck Cancers: Implications for Clinical Management. Journal of Medical Virology, 96, e29746. [Google Scholar] [CrossRef] [PubMed]
[4] Tan, K.T., Yeh, C., Chang, Y., Cheng, J., Fang, W., Yeh, Y., et al. (2020) PRKDC: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000485. [Google Scholar] [CrossRef] [PubMed]
[5] Scampa, M., Merat, R., Kalbermatten, D.F. and Oranges, C.M. (2022) Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival. Journal of Clinical Medicine, 11, Article 2185. [Google Scholar] [CrossRef] [PubMed]
[6] Li, C., Wang, D.R., Sun, R.H. and Zhang, Z.Y. (2025) Current Status and Future Directions of the Diagnosis and Treatment for Head and Neck Tumor in China. National Medical Journal of China, 105, 1567-1571.
[7] Chen, X., Hao, Y., Chou, M. and Yang, J. (2024) Epidemiology of the Non-Head and Neck Sebaceous Carcinoma and Implications for Distant Metastasis Screening. Frontiers in Oncology, 14, Article 1395273. [Google Scholar] [CrossRef] [PubMed]
[8] Soleimani, F., Babaei, E., H. Feizi, M.A. and Fathi, F. (2019) CRISPR‐Cas9‐Mediated Knockout of the PRKDC in Mouse Embryonic Stem Cells Leads to the Modulation of the Expression of Pluripotency Genes. Journal of Cellular Physiology, 235, 3994-4000. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, Z., Li, K., Zhang, X., Jiang, F. and Xu, L. (2025) LINC00942 Accelerates Esophageal Cancer Progression by Raising PRKDC through Interaction with PTBP1. Journal of Biochemical and Molecular Toxicology, 39, e70220. [Google Scholar] [CrossRef] [PubMed]
[10] Zhou, Y., Liu, F., Xu, Q., Yang, B., Li, X., Jiang, S., et al. (2020) Inhibiting Importin 4-Mediated Nuclear Import of CEBPD Enhances Chemosensitivity by Repression of PRKDC-Driven DNA Damage Repair in Cervical Cancer. Oncogene, 39, 5633-5648. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, Y., Yang, W., Wen, G., Tang, H., Wu, C., Wu, Y., et al. (2019) High Expression of PRKDC Promotes Breast Cancer Cell Growth via p38 MAPK Signaling and Is Associated with Poor Survival. Molecular Genetics & Genomic Medicine, 7, e908. [Google Scholar] [CrossRef] [PubMed]
[12] Takagi, Y., Sudo, K., Yamaguchi, S., Urata, S., Ohno, T., Hirose, S., et al. (2023) Characterization of Novel, Severely Immunodeficient PRKDC Mice. Biochemical and Biophysical Research Communications, 678, 193-199. [Google Scholar] [CrossRef] [PubMed]
[13] Yang, X., Yang, F., Lan, L., Wen, N., Li, H. and Sun, X. (2022) Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-Cancer. Medicine, 101, e29628. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, W., Li, W., Yin, C., Feng, C., Liu, B., Xu, H., et al. (2024) PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT. Cancer Research, 84, 2873-2887. [Google Scholar] [CrossRef] [PubMed]
[15] Pang, W., Wang, Y., Lu, X., Li, M., Long, F., Chen, S., et al. (2025) Integrated Spatial and Single Cell Transcriptomics Identifies PRKDC as a Dual Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Scientific Reports, 15, Article No. 14834. [Google Scholar] [CrossRef] [PubMed]
[16] Senghore, T., Wang, W., Chien, H., Chen, Y., Young, C., Huang, S., et al. (2021) Association of XRCC2 Rs2040639 with the Survival of Patients with Oral Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy. Gene, 768, Article ID: 145283. [Google Scholar] [CrossRef] [PubMed]
[17] Zhan, Q.Y., Xie, L.X. and Wang, C. (2023) Promoting Critical Care System and Capacity Building in Pulmonary and Critical Care Medicine Subspecialties. National Medical Journal of China, 103, 3149-3151.
[18] Li, R., Wu, G., Fang, X., Yang, W., Zhang, H., Yue, H., et al. (2025) Single-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting. Drug Design, Development and Therapy, 19, 2897-2920. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, Y., Li, Y., Guan, Y., Huang, Y., Lin, J., Chen, L., et al. (2020) Prevalence of PRKDC Mutations and Association with Response to Immune Checkpoint Inhibitors in Solid Tumors. Molecular Oncology, 14, 2096-2110. [Google Scholar] [CrossRef] [PubMed]
[20] Pan, Y., Zhu, Q., Hong, T., Cheng, J. and Tang, X. (2024) Targeting PRKDC Activates the Efficacy of Antitumor Immunity While Sensitizing to Chemotherapy and Targeted Therapy in Liver Hepatocellular Carcinoma. Aging, 16, 9047-9071. [Google Scholar] [CrossRef] [PubMed]
[21] Han, B., Chen, J., Chen, S., Shen, X., Hou, L., Fang, J., et al. (2024) PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma. PPAR Research, 2024, 1-8. [Google Scholar] [CrossRef] [PubMed]
[22] Xiong, J., Deng, C., Fu, Y., Tang, J., Xie, J. and Chen, Y. (2024) Prognostic and Potential Therapeutic Roles of PRKDC Expression in Lung Cancer. Molecular Biotechnology, 67, 2455-2466. [Google Scholar] [CrossRef] [PubMed]
[23] Ling, Z., Fang, Z., Wu, J. and Liu, J. (2021) The Depletion of CIRC‐PRKDC Enhances Autophagy and Apoptosis in T‐Cell Acute Lymphoblastic Leukemia via MicroRNA‐653‐5p/Reelin Mediation of the PI3K/AKT/mTOR Signaling Pathway. The Kaohsiung Journal of Medical Sciences, 37, 392-401. [Google Scholar] [CrossRef] [PubMed]
[24] Gao, X., Fan, X., Zeng, W., Liang, J., Guo, N., Yang, X., et al. (2022) Overexpression of MicroRNA-107 Suppressed Proliferation, Migration, Invasion, and the PI3K/AKT Signaling Pathway and Induced Apoptosis by Targeting Nin One Binding (NOB1) Protein in a Hypopharyngeal Squamous Cell Carcinoma Cell Line (FADU). Bioengineered, 13, 7880-7892. [Google Scholar] [CrossRef] [PubMed]
[25] Peng, H. and Ge, P. (2021) Long Non-Coding RNA HCG18 Facilitates the Progression of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma by Upregulating FGFR1 via miR-133b. Molecular Medicine Reports, 25, 46. [Google Scholar] [CrossRef] [PubMed]
[26] Rasteh, A.M., Liu, H. and Wang, P. (2024) Pan-Cancer Genetic Profiles of Mitotic DNA Integrity Checkpoint Protein Kinases. Cancer Biomarker, 41, CBM240119.
[27] Fang, J., Singh, S., Cheng, C., Natarajan, S., Sheppard, H., Abu-Zaid, A., et al. (2023) Genome-Wide Mapping of Cancer Dependency Genes and Genetic Modifiers of Chemotherapy in High-Risk Hepatoblastoma. Nature Communications, 14, Article No. 4003. [Google Scholar] [CrossRef] [PubMed]
[28] Yanes-Díaz, J., Palao-Suay, R., Camacho-Castañeda, F.I., Riestra-Ayora, J., Aguilar, M.R., Sanz-Fernández, R., et al. (2025) In Vivo Antitumor Activity of PHT-427 Inhibitor-Loaded Polymeric Nanoparticles in Head and Neck Squamous Cell Carcinoma. Drug Delivery, 32, Article ID: 2449376. [Google Scholar] [CrossRef] [PubMed]
[29] Chen, X., Xu, Y., Jiang, L. and Tan, Q. (2021) miRNA‐218‐5p Increases Cell Sensitivity by Inhibiting PRKDC Activity in Radiation‐Resistant Lung Carcinoma Cells. Thoracic Cancer, 12, 1549-1557. [Google Scholar] [CrossRef] [PubMed]

为你推荐